# CD74

> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/CD74
> Markdown URL: https://mediated.wiki/source/CD74.md
> Source: https://en.wikipedia.org/wiki/CD74
> Source revision: 1354255855
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)

Mammalian protein found in humans

CD74 Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 1A6A, 1ICF, 1IIE, 1L3H, 1MUJ, 3PDO, 3PGC, 3PGD, 3QXA, 3QXD, 4AEN, 4X5W Identifiers Aliases CD74, DHLAG, HLADG, II, Ia-GAMMA, CD74 molecule, p33, CLIP External IDs OMIM: 142790; MGI: 96534; HomoloGene: 3209; GeneCards: CD74; OMA:CD74 - orthologs Gene location (Human) Chr. Chromosome 5 (human)[1] Band 5q33.1 Start 150,401,637 bp[1] End 150,412,969 bp[1] Gene location (Mouse) Chr. Chromosome 18 (mouse)[2] Band 18 E1|18 34.41 cM Start 60,936,920 bp[2] End 60,945,724 bp[2] RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in monocyte appendix granulocyte spleen lymph node right lung gallbladder upper lobe of left lung lower lobe of lung mucosa of ileum Top expressed in spleen jejunum thymus ileum zone of skin colon lip uterus adrenal gland white adipose tissue More reference expression data BioGPS More reference expression data Gene ontology Molecular function nitric-oxide synthase binding identical protein binding MHC class II protein binding, via antigen binding groove cytokine receptor activity macrophage migration inhibitory factor binding protein folding chaperone activity MHC class II protein complex binding amyloid-beta binding protein binding MHC class II protein binding cytokine binding CD4 receptor binding Cellular component lysosomal lumen extracellular exosome MHC class II protein complex lysosomal membrane late endosome endocytic vesicle membrane transport vesicle membrane integral component of membrane ER to Golgi transport vesicle membrane multivesicular body Golgi apparatus Golgi membrane trans-Golgi network membrane macrophage migration inhibitory factor receptor complex membrane cell surface intracellular anatomical structure integral component of lumenal side of endoplasmic reticulum membrane endoplasmic reticulum endoplasmic reticulum membrane plasma membrane lysosome vacuole endosome clathrin-coated endocytic vesicle membrane NOS2-CD74 complex external side of plasma membrane Biological process immune response positive regulation of T cell differentiation negative regulation of apoptotic process signal transduction positive thymic T cell selection chaperone cofactor-dependent protein refolding T cell selection positive regulation of type 2 immune response positive regulation of dendritic cell antigen processing and presentation antigen processing and presentation of exogenous peptide antigen via MHC class II adaptive immune response antigen processing and presentation positive regulation of peptidyl-tyrosine phosphorylation negative regulation of mature B cell apoptotic process regulation of macrophage activation negative regulation of DNA damage response, signal transduction by p53 class mediator immunoglobulin mediated immune response leukocyte migration positive regulation of neutrophil chemotaxis positive regulation of chemokine (C-X-C motif) ligand 2 production macrophage migration inhibitory factor signaling pathway prostaglandin biosynthetic process cell population proliferation antigen processing and presentation of endogenous antigen immune system process defense response negative regulation of peptide secretion negative regulation of T cell differentiation positive regulation of macrophage cytokine production positive regulation of B cell proliferation negative thymic T cell selection positive regulation of fibroblast proliferation intracellular protein transport positive regulation of ERK1 and ERK2 cascade negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator positive regulation of cytokine-mediated signaling pathway positive regulation of protein phosphorylation positive regulation of kinase activity positive regulation of I-kappaB kinase/NF-kappaB signaling positive regulation of MAPK cascade positive regulation of monocyte differentiation positive regulation of transcription, DNA-templated positive regulation of viral entry into host cell protein heterotetramerization protein trimerization protein-containing complex assembly Sources:Amigo / QuickGO Orthologs Species Human Mouse Entrez 972 16149 Ensembl ENSG00000019582 ENSMUSG00000024610 UniProt P04233 P04441 RefSeq (mRNA) NM_004355 NM_001025158 NM_001025159 NM_001364083 NM_001364084 NM_001042605 NM_010545 RefSeq (protein) NP_001020329 NP_001020330 NP_004346 NP_001351012 NP_001351013 NP_001036070 NP_034675 Location (UCSC) Chr 5: 150.4 – 150.41 Mb Chr 18: 60.94 – 60.95 Mb PubMed search [3] [4] Wikidata View/Edit Human View/Edit Mouse

**HLA class II histocompatibility antigen gamma chain** also known as **HLA-DR antigens-associated invariant chain** or **CD74** (**C**luster of **D**ifferentiation 74), is a [protein](/source/Protein) that in humans is encoded by the *CD74* [gene](/source/Gene).[5][6] The **invariant chain** (Abbreviated **Ii**) is a [polypeptide](/source/Peptide) which plays a critical role in [antigen presentation](/source/Antigen_presentation). It is involved in the formation and transport of [MHC class II](/source/MHC_class_II) peptide complexes for the generation of [CD4+ T cell](/source/T_helper_cell) responses.[7][8] The cell surface form of the invariant chain is known as CD74. CD74 is a [cell surface receptor](/source/Cell_surface_receptor) for the cytokine [macrophage migration inhibitory factor](/source/Macrophage_migration_inhibitory_factor) (MIF).[9]

## Function

The nascent [MHC](/source/Major_histocompatibility_complex) class II protein in the [rough endoplasmic reticulum](/source/Endoplasmic_reticulum#Rough_endoplasmic_reticulum) (RER) binds a segment of the invariant chain (Ii; a trimer) in order to shape the peptide-binding groove and prevent the formation of a closed conformation.

The invariant chain also facilitates the export of MHC class II from the RER in a vesicle. The signal for endosomal targeting resides in the cytoplasmic tail of the invariant chain. This fuses with a late [endosome](/source/Endosome) containing the endocytosed antigen proteins (from the exogenous pathway). Binding to Ii ensures that no antigen peptides from the endogenous pathway meant for [MHC class I](/source/MHC_class_I) molecules accidentally bind to the groove of MHC class II molecules.[10] The Ii is then cleaved by [cathepsin S](/source/Cathepsin_S) ([cathepsin L](/source/Cathepsin_L1) in [cortical thymic epithelial cells](/source/Cortical_thymic_epithelial_cells)), leaving only a small fragment called [CLIP](/source/CLIP_(protein)) remaining bound to the groove of MHC class II molecules. The rest of the Ii is degraded.[10] CLIP blocks peptide-binding until [HLA-DM](/source/HLA-DM) interacts with MHC II, releasing CLIP and allowing other peptides to bind. In some cases, CLIP dissociates without any further molecular interactions, but in other cases the binding to the MHC is more stable.[11]

The stable MHC class II + antigen complex is then [presented](/source/Antigen_presentation) on the cell surface. Without CLIP, MHC class II aggregates disassemble and/or denature in the endosomes, and proper antigen presentation is impaired.[12]

## Clinical significance

### Vaccine adjuvant

The Ii molecule—fused with a [viral vector](/source/Viral_vector) to a [conserved region](/source/Conserved_sequence) of the [Hepatitis C virus](/source/Hepatitis_C_virus) (HCV) genome—has been tested as an [adjuvant](/source/Adjuvant) for a [HCV vaccine](/source/Hepatitis_C_vaccine) in a cohort of 17 healthy human volunteers. This experimental vaccine was well-tolerated, and those who received the adjuvanted vaccine had stronger anti-HCV immune responses (enhanced magnitude, breadth and proliferative capacity of anti-HCV-specific T-cells) compared with volunteers who received the vaccine that lacked the Ii adjuvant.[13]

The Ii molecule might also prove to be useful as an adjuvant for a future [vaccine for the SARS-CoV-2 virus](/source/COVID-19_vaccine), if this enhancing effect can be demonstrated to apply to the appropriate antigen(s).[14]

### Cancer

Found on a number of cancer cell types. Possible cancer therapy target. See [milatuzumab](/source/Milatuzumab#CD74).

### Axial spondyloarthritis

[Autoantibodies](/source/Autoantibodies) against CD74 have been identified as promising [biomarkers](/source/Biomarkers) in the early diagnosis of the [autoimmune disease](/source/Autoimmune_disease) called [axial spondyloarthritis](/source/Axial_spondyloarthritis) ([non-radiographic axial spondyloarthritis](/source/Non-radiographic_axial_spondyloarthritis) and [radiographic axial spondyloarthritis](/source/Radiographic_axial_spondyloarthritis) / [Ankylosing spondylitis](/source/Ankylosing_spondylitis)).[15]

## Interactions

CD74 receptor [interacts](/source/Protein-protein_interaction) with the cytokine [Macrophage migration inhibitory factor](/source/Macrophage_migration_inhibitory_factor) (MIF) to mediate some of its functions.[16][17][18][19][20][21]

## Recovery functions

Role of CD74 receptor in tissue injury and wound repair

CD74 receptor is expressed on the surface of different cell types. Interaction between MIF cytokine and its cell membrane receptor CD74 activates pro-survival and proliferative pathways that protect against injury and promote healing in different parts of the body.[22]

## History

The invariant chain was first described by Patricia P. Jones, Donal B. Murphy, Derek Hewgill, and [Hugh McDevitt](/source/Hugh_McDevitt) at Stanford.[23] The nomenclature "Ii" comes from an Ix-based naming system (*I* for *I*mmune) that predates the naming of the [Major Histocompatibility Complex](/source/Major_histocompatibility_complex).

## See also

- [Cluster of differentiation](/source/Cluster_of_differentiation)

- [Milatuzumab](/source/Milatuzumab) the first Mab to target CD74

## References

1. ^ [***a***](#cite_ref-refGRCh38Ensembl_1-0) [***b***](#cite_ref-refGRCh38Ensembl_1-1) [***c***](#cite_ref-refGRCh38Ensembl_1-2) [GRCh38: Ensembl release 89: ENSG00000019582](http://May2017.archive.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000019582) – [Ensembl](/source/Ensembl_genome_database_project), May 2017

1. ^ [***a***](#cite_ref-refGRCm38Ensembl_2-0) [***b***](#cite_ref-refGRCm38Ensembl_2-1) [***c***](#cite_ref-refGRCm38Ensembl_2-2) [GRCm38: Ensembl release 89: ENSMUSG00000024610](http://May2017.archive.ensembl.org/Mus_musculus/Gene/Summary?db=core;g=ENSMUSG00000024610) – [Ensembl](/source/Ensembl_genome_database_project), May 2017

1. **[^](#cite_ref-3)** ["Human PubMed Reference:"](https://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&cmd=Link&LinkName=gene_pubmed&from_uid=972). *National Center for Biotechnology Information, U.S. National Library of Medicine*.

1. **[^](#cite_ref-4)** ["Mouse PubMed Reference:"](https://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&cmd=Link&LinkName=gene_pubmed&from_uid=16149). *National Center for Biotechnology Information, U.S. National Library of Medicine*.

1. **[^](#cite_ref-pmid6324166_5-0)** Claesson L, Larhammar D, Rask L, Peterson PA (December 1983). ["cDNA clone for the human invariant gamma chain of class II histocompatibility antigens and its implications for the protein structure"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC389957). *Proceedings of the National Academy of Sciences of the United States of America*. **80** (24): 7395–7399. [Bibcode](/source/Bibcode_(identifier)):[1983PNAS...80.7395C](https://ui.adsabs.harvard.edu/abs/1983PNAS...80.7395C). [doi](/source/Doi_(identifier)):[10.1073/pnas.80.24.7395](https://doi.org/10.1073%2Fpnas.80.24.7395). [PMC](/source/PMC_(identifier)) [389957](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC389957). [PMID](/source/PMID_(identifier)) [6324166](https://pubmed.ncbi.nlm.nih.gov/6324166).

1. **[^](#cite_ref-pmid3001652_6-0)** Kudo J, Chao LY, Narni F, Saunders GF (December 1985). ["Structure of the human gene encoding the invariant gamma-chain of class II histocompatibility antigens"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC318954). *Nucleic Acids Research*. **13** (24): 8827–8841. [doi](/source/Doi_(identifier)):[10.1093/nar/13.24.8827](https://doi.org/10.1093%2Fnar%2F13.24.8827). [PMC](/source/PMC_(identifier)) [318954](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC318954). [PMID](/source/PMID_(identifier)) [3001652](https://pubmed.ncbi.nlm.nih.gov/3001652).

1. **[^](#cite_ref-UniProt_7-0)** ["UniProtKB - P04233 (HG2A_HUMAN)"](https://www.uniprot.org/uniprot/P04233). *The UniProt Knowledgebase*. The UniProt Consortium. 2020. Retrieved Aug 10, 2020.

1. **[^](#cite_ref-pmid8011283_8-0)** Cresswell P (1994). "Assembly, transport, and function of MHC class II molecules". *Annual Review of Immunology*. **12**: 259–293. [doi](/source/Doi_(identifier)):[10.1146/annurev.iy.12.040194.001355](https://doi.org/10.1146%2Fannurev.iy.12.040194.001355). [PMID](/source/PMID_(identifier)) [8011283](https://pubmed.ncbi.nlm.nih.gov/8011283).

1. **[^](#cite_ref-9)** Farr L, Ghosh S, Moonah S (2020). ["Role of MIF Cytokine/CD74 Receptor Pathway in Protecting Against Injury and Promoting Repair"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325688). *Frontiers in Immunology*. **11**: 1273. [doi](/source/Doi_(identifier)):[10.3389/fimmu.2020.01273](https://doi.org/10.3389%2Ffimmu.2020.01273). [PMC](/source/PMC_(identifier)) [7325688](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325688). [PMID](/source/PMID_(identifier)) [32655566](https://pubmed.ncbi.nlm.nih.gov/32655566).

1. ^ [***a***](#cite_ref-Kuby_2013_10-0) [***b***](#cite_ref-Kuby_2013_10-1) Owen JA, Punt J, Stranford SA, Jones PP, Kuby J (2013). *Kuby immunology* (7th ed.). New York: W.H. Freeman. [ISBN](/source/ISBN_(identifier)) [978-1-4641-1991-0](https://en.wikipedia.org/wiki/Special:BookSources/978-1-4641-1991-0). [OCLC](/source/OCLC_(identifier)) [820117219](https://search.worldcat.org/oclc/820117219).

1. **[^](#cite_ref-Schulze_2012_11-0)** Schulze MS, Wucherpfennig KW (February 2012). ["The mechanism of HLA-DM induced peptide exchange in the MHC class II antigen presentation pathway"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3288754). *Current Opinion in Immunology*. **24** (1): 105–111. [doi](/source/Doi_(identifier)):[10.1016/j.coi.2011.11.004](https://doi.org/10.1016%2Fj.coi.2011.11.004). [PMC](/source/PMC_(identifier)) [3288754](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3288754). [PMID](/source/PMID_(identifier)) [22138314](https://pubmed.ncbi.nlm.nih.gov/22138314).

1. **[^](#cite_ref-Vogt_1999_12-0)** Vogt AB, Kropshofer H (April 1999). "HLA-DM - an endosomal and lysosomal chaperone for the immune system". *Trends in Biochemical Sciences*. **24** (4): 150–154. [doi](/source/Doi_(identifier)):[10.1016/s0968-0004(99)01364-x](https://doi.org/10.1016%2Fs0968-0004%2899%2901364-x). [PMID](/source/PMID_(identifier)) [10322421](https://pubmed.ncbi.nlm.nih.gov/10322421).

1. **[^](#cite_ref-Esposito2020_13-0)** Esposito I, Cicconi P, D'Alise AM, Brown A, Esposito M, Swadling L, et al. (June 2020). ["MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610808). *Science Translational Medicine*. **12** (548) eaaz7715. [doi](/source/Doi_(identifier)):[10.1126/scitranslmed.aaz7715](https://doi.org/10.1126%2Fscitranslmed.aaz7715). [PMC](/source/PMC_(identifier)) [7610808](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610808). [PMID](/source/PMID_(identifier)) [32554708](https://pubmed.ncbi.nlm.nih.gov/32554708). [S2CID](/source/S2CID_(identifier)) [219722045](https://api.semanticscholar.org/CorpusID:219722045).

1. **[^](#cite_ref-GIHF2020_14-0)** Larkin M (June 24, 2020). ["Adjuvanted viral-vectored vaccine promising against hepatitis C in early trial"](https://www.gihealthfoundation.org/reuters/article.cfm?article=20200624Other669656573&cat=Othe&dstate=GI). *Reuters Health News*. GI Health Foundation. Retrieved Aug 10, 2020.

1. **[^](#cite_ref-15)** Baerlecken NT, Nothdorft S, Stummvoll GH, Sieper J, Rudwaleit M, Reuter S, et al. (June 2014). "Autoantibodies against CD74 in spondyloarthritis". *Annals of the Rheumatic Diseases*. **73** (6): 1211–1214. [doi](/source/Doi_(identifier)):[10.1136/annrheumdis-2012-202208](https://doi.org/10.1136%2Fannrheumdis-2012-202208). [PMID](/source/PMID_(identifier)) [23687263](https://pubmed.ncbi.nlm.nih.gov/23687263). [S2CID](/source/S2CID_(identifier)) [22939188](https://api.semanticscholar.org/CorpusID:22939188).

1. **[^](#cite_ref-16)** Ghosh S, Padalia J, Ngobeni R, Abendroth J, Farr L, Shirley DA, et al. (March 2020). ["Targeting Parasite-Produced Macrophage Migration Inhibitory Factor as an Antivirulence Strategy With Antibiotic-Antibody Combination to Reduce Tissue Damage"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325720). *The Journal of Infectious Diseases*. **221** (7): 1185–1193. [doi](/source/Doi_(identifier)):[10.1093/infdis/jiz579](https://doi.org/10.1093%2Finfdis%2Fjiz579). [PMC](/source/PMC_(identifier)) [7325720](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325720). [PMID](/source/PMID_(identifier)) [31677380](https://pubmed.ncbi.nlm.nih.gov/31677380).

1. **[^](#cite_ref-17)** Shan ZX, Lin QX, Deng CY, Tan HH, Kuang SJ, Xiao DZ, et al. (December 2009). "[Identification of the interactions between the truncated fragments of macrophage migration inhibitory factor and CD74 using a yeast two-hybrid system]". *Nan Fang Yi Ke da Xue Xue Bao = Journal of Southern Medical University* (in Chinese). **29** (12): 2383–6, 2390. [PMID](/source/PMID_(identifier)) [20034881](https://pubmed.ncbi.nlm.nih.gov/20034881).

1. **[^](#cite_ref-18)** Wang F, Shen X, Guo X, Peng Y, Liu Y, Xu S, Yang J (February 2010). "Spinal macrophage migration inhibitory factor contributes to the pathogenesis of inflammatory hyperalgesia in rats". *Pain*. **148** (2): 275–283. [doi](/source/Doi_(identifier)):[10.1016/j.pain.2009.11.011](https://doi.org/10.1016%2Fj.pain.2009.11.011). [PMID](/source/PMID_(identifier)) [20005040](https://pubmed.ncbi.nlm.nih.gov/20005040). [S2CID](/source/S2CID_(identifier)) [38141283](https://api.semanticscholar.org/CorpusID:38141283).

1. **[^](#cite_ref-19)** Dobson SE, Augustijn KD, Brannigan JA, Schnick C, Janse CJ, Dodson EJ, et al. (December 2009). ["The crystal structures of macrophage migration inhibitory factor from Plasmodium falciparum and Plasmodium berghei"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2798171). *Protein Science*. **18** (12): 2578–2591. [doi](/source/Doi_(identifier)):[10.1002/pro.263](https://doi.org/10.1002%2Fpro.263). [PMC](/source/PMC_(identifier)) [2798171](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2798171). [PMID](/source/PMID_(identifier)) [19827093](https://pubmed.ncbi.nlm.nih.gov/19827093).

1. **[^](#cite_ref-20)** Piette C, Deprez M, Roger T, Noël A, Foidart JM, Munaut C (November 2009). ["The dexamethasone-induced inhibition of proliferation, migration, and invasion in glioma cell lines is antagonized by macrophage migration inhibitory factor (MIF) and can be enhanced by specific MIF inhibitors"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2781663). *The Journal of Biological Chemistry*. **284** (47): 32483–32492. [doi](/source/Doi_(identifier)):[10.1074/jbc.M109.014589](https://doi.org/10.1074%2Fjbc.M109.014589). [PMC](/source/PMC_(identifier)) [2781663](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2781663). [PMID](/source/PMID_(identifier)) [19759012](https://pubmed.ncbi.nlm.nih.gov/19759012).

1. **[^](#cite_ref-21)** Verjans E, Noetzel E, Bektas N, Schütz AK, Lue H, Lennartz B, et al. (July 2009). ["Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716369). *BMC Cancer*. **9** 230. [doi](/source/Doi_(identifier)):[10.1186/1471-2407-9-230](https://doi.org/10.1186%2F1471-2407-9-230). [PMC](/source/PMC_(identifier)) [2716369](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716369). [PMID](/source/PMID_(identifier)) [19602265](https://pubmed.ncbi.nlm.nih.gov/19602265).

1. **[^](#cite_ref-22)** Farr L, Ghosh S, Moonah S (2020). ["Role of MIF Cytokine/CD74 Receptor Pathway in Protecting Against Injury and Promoting Repair"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325688). *Frontiers in Immunology*. **11**: 1273. [doi](/source/Doi_(identifier)):[10.3389/fimmu.2020.01273](https://doi.org/10.3389%2Ffimmu.2020.01273). [PMC](/source/PMC_(identifier)) [7325688](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325688). [PMID](/source/PMID_(identifier)) [32655566](https://pubmed.ncbi.nlm.nih.gov/32655566).

1. **[^](#cite_ref-23)** Jones PP, Murphy DB, Hewgill D, McDevitt HO (January 1979). "Detection of a common polypeptide chain in I--A and I--E sub-region immunoprecipitates". *Molecular Immunology*. **16** (1): 51–60. [doi](/source/Doi_(identifier)):[10.1016/0161-5890(79)90027-0](https://doi.org/10.1016%2F0161-5890%2879%2990027-0). [PMID](/source/PMID_(identifier)) [376435](https://pubmed.ncbi.nlm.nih.gov/376435).

## Further reading

- Stove V, Verhasselt B (January 2006). "Modelling thymic HIV-1 Nef effects". *Current HIV Research*. **4** (1): 57–64. [doi](/source/Doi_(identifier)):[10.2174/157016206775197583](https://doi.org/10.2174%2F157016206775197583). [PMID](/source/PMID_(identifier)) [16454711](https://pubmed.ncbi.nlm.nih.gov/16454711).

- Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P (December 1992). "HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides". *Nature*. **360** (6403): 474–477. [Bibcode](/source/Bibcode_(identifier)):[1992Natur.360..474R](https://ui.adsabs.harvard.edu/abs/1992Natur.360..474R). [doi](/source/Doi_(identifier)):[10.1038/360474a0](https://doi.org/10.1038%2F360474a0). [PMID](/source/PMID_(identifier)) [1448172](https://pubmed.ncbi.nlm.nih.gov/1448172). [S2CID](/source/S2CID_(identifier)) [4338656](https://api.semanticscholar.org/CorpusID:4338656).

- Bakke O, Dobberstein B (November 1990). ["MHC class II-associated invariant chain contains a sorting signal for endosomal compartments"](https://archiv.ub.uni-heidelberg.de/volltextserver/9193/1/27.MHC_class_II_associated_invariant_chain.pdf) (PDF). *Cell*. **63** (4): 707–716. [doi](/source/Doi_(identifier)):[10.1016/0092-8674(90)90137-4](https://doi.org/10.1016%2F0092-8674%2890%2990137-4). [PMID](/source/PMID_(identifier)) [2121367](https://pubmed.ncbi.nlm.nih.gov/2121367). [S2CID](/source/S2CID_(identifier)) [19993336](https://api.semanticscholar.org/CorpusID:19993336).

- Marks MS, Blum JS, Cresswell P (September 1990). ["Invariant chain trimers are sequestered in the rough endoplasmic reticulum in the absence of association with HLA class II antigens"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2116304). *The Journal of Cell Biology*. **111** (3): 839–855. [doi](/source/Doi_(identifier)):[10.1083/jcb.111.3.839](https://doi.org/10.1083%2Fjcb.111.3.839). [PMC](/source/PMC_(identifier)) [2116304](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2116304). [PMID](/source/PMID_(identifier)) [2391366](https://pubmed.ncbi.nlm.nih.gov/2391366).

- Spiro RC, Quaranta V (October 1989). ["The invariant chain is a phosphorylated subunit of class II molecules"](https://doi.org/10.4049%2Fjimmunol.143.8.2589). *Journal of Immunology*. **143** (8): 2589–2594. [doi](/source/Doi_(identifier)):[10.4049/jimmunol.143.8.2589](https://doi.org/10.4049%2Fjimmunol.143.8.2589). [PMID](/source/PMID_(identifier)) [2507633](https://pubmed.ncbi.nlm.nih.gov/2507633). [S2CID](/source/S2CID_(identifier)) [6755576](https://api.semanticscholar.org/CorpusID:6755576).

- O'Sullivan DM, Noonan D, Quaranta V (August 1987). ["Four Ia invariant chain forms derive from a single gene by alternate splicing and alternate initiation of transcription/translation"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2189580). *The Journal of Experimental Medicine*. **166** (2): 444–460. [doi](/source/Doi_(identifier)):[10.1084/jem.166.2.444](https://doi.org/10.1084%2Fjem.166.2.444). [PMC](/source/PMC_(identifier)) [2189580](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2189580). [PMID](/source/PMID_(identifier)) [3036998](https://pubmed.ncbi.nlm.nih.gov/3036998).

- Genuardi M, Saunders GF (1988). "Localization of the HLA class II-associated invariant chain gene to human chromosome band 5q32". *Immunogenetics*. **28** (1): 53–56. [doi](/source/Doi_(identifier)):[10.1007/BF00372530](https://doi.org/10.1007%2FBF00372530). [PMID](/source/PMID_(identifier)) [3132422](https://pubmed.ncbi.nlm.nih.gov/3132422). [S2CID](/source/S2CID_(identifier)) [2418453](https://api.semanticscholar.org/CorpusID:2418453).

- O'Sullivan DM, Larhammar D, Wilson MC, Peterson PA, Quaranta V (June 1986). ["Structure of the human Ia-associated invariant (gamma)-chain gene: identification of 5' sequences shared with major histocompatibility complex class II genes"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC323758). *Proceedings of the National Academy of Sciences of the United States of America*. **83** (12): 4484–4488. [Bibcode](/source/Bibcode_(identifier)):[1986PNAS...83.4484O](https://ui.adsabs.harvard.edu/abs/1986PNAS...83.4484O). [doi](/source/Doi_(identifier)):[10.1073/pnas.83.12.4484](https://doi.org/10.1073%2Fpnas.83.12.4484). [PMC](/source/PMC_(identifier)) [323758](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC323758). [PMID](/source/PMID_(identifier)) [3459184](https://pubmed.ncbi.nlm.nih.gov/3459184).

- Koch N, Hämmerling GJ (October 1985). "Ia-associated invariant chain is fatty acylated before addition of sialic acid". *Biochemistry*. **24** (22): 6185–6190. [doi](/source/Doi_(identifier)):[10.1021/bi00343a023](https://doi.org/10.1021%2Fbi00343a023). [PMID](/source/PMID_(identifier)) [3866610](https://pubmed.ncbi.nlm.nih.gov/3866610).

- Claesson L, Peterson PA (June 1983). "Association of human gamma chain with class II transplantation antigens during intracellular transport". *Biochemistry*. **22** (13): 3206–3213. [doi](/source/Doi_(identifier)):[10.1021/bi00282a026](https://doi.org/10.1021%2Fbi00282a026). [PMID](/source/PMID_(identifier)) [6576808](https://pubmed.ncbi.nlm.nih.gov/6576808).

- Strubin M, Mach B, Long EO (April 1984). ["The complete sequence of the mRNA for the HLA-DR-associated invariant chain reveals a polypeptide with an unusual transmembrane polarity"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC557440). *The EMBO Journal*. **3** (4): 869–872. [doi](/source/Doi_(identifier)):[10.1002/j.1460-2075.1984.tb01898.x](https://doi.org/10.1002%2Fj.1460-2075.1984.tb01898.x). [PMC](/source/PMC_(identifier)) [557440](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC557440). [PMID](/source/PMID_(identifier)) [6586420](https://pubmed.ncbi.nlm.nih.gov/6586420).

- Kvist S, Wiman K, Claesson L, Peterson PA, Dobberstein B (May 1982). ["Membrane insertion and oligomeric assembly of HLA-DR histocompatibility antigens"](https://archiv.ub.uni-heidelberg.de/volltextserver/9169/1/10.Membrane_insertion_and_oligomeric_assembly.pdf) (PDF). *Cell*. **29** (1): 61–69. [doi](/source/Doi_(identifier)):[10.1016/0092-8674(82)90090-3](https://doi.org/10.1016%2F0092-8674%2882%2990090-3). [PMID](/source/PMID_(identifier)) [6955026](https://pubmed.ncbi.nlm.nih.gov/6955026). [S2CID](/source/S2CID_(identifier)) [9066996](https://api.semanticscholar.org/CorpusID:9066996).

- Machamer CE, Cresswell P (December 1982). "Biosynthesis and glycosylation of the invariant chain associated with HLA-DR antigens". *Journal of Immunology*. **129** (6): 2564–2569. [doi](/source/Doi_(identifier)):[10.4049/jimmunol.129.6.2564](https://doi.org/10.4049%2Fjimmunol.129.6.2564). [PMID](/source/PMID_(identifier)) [6982931](https://pubmed.ncbi.nlm.nih.gov/6982931). [S2CID](/source/S2CID_(identifier)) [42620266](https://api.semanticscholar.org/CorpusID:42620266).

- Ghosh P, Amaya M, Mellins E, Wiley DC (November 1995). "The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3". *Nature*. **378** (6556): 457–462. [Bibcode](/source/Bibcode_(identifier)):[1995Natur.378..457G](https://ui.adsabs.harvard.edu/abs/1995Natur.378..457G). [doi](/source/Doi_(identifier)):[10.1038/378457a0](https://doi.org/10.1038%2F378457a0). [PMID](/source/PMID_(identifier)) [7477400](https://pubmed.ncbi.nlm.nih.gov/7477400). [S2CID](/source/S2CID_(identifier)) [4275956](https://api.semanticscholar.org/CorpusID:4275956).

- Bijlmakers MJ, Benaroch P, Ploegh HL (August 1994). ["Mapping functional regions in the lumenal domain of the class II-associated invariant chain"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2191624). *The Journal of Experimental Medicine*. **180** (2): 623–629. [doi](/source/Doi_(identifier)):[10.1084/jem.180.2.623](https://doi.org/10.1084%2Fjem.180.2.623). [PMC](/source/PMC_(identifier)) [2191624](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2191624). [PMID](/source/PMID_(identifier)) [7519244](https://pubmed.ncbi.nlm.nih.gov/7519244).

- Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, Wiley DC (July 1993). "Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1". *Nature*. **364** (6432): 33–39. [Bibcode](/source/Bibcode_(identifier)):[1993Natur.364...33B](https://ui.adsabs.harvard.edu/abs/1993Natur.364...33B). [doi](/source/Doi_(identifier)):[10.1038/364033a0](https://doi.org/10.1038%2F364033a0). [PMID](/source/PMID_(identifier)) [8316295](https://pubmed.ncbi.nlm.nih.gov/8316295). [S2CID](/source/S2CID_(identifier)) [4248668](https://api.semanticscholar.org/CorpusID:4248668).

- Naujokas MF, Morin M, Anderson MS, Peterson M, Miller J (July 1993). "The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44". *Cell*. **74** (2): 257–268. [doi](/source/Doi_(identifier)):[10.1016/0092-8674(93)90417-O](https://doi.org/10.1016%2F0092-8674%2893%2990417-O). [PMID](/source/PMID_(identifier)) [8343954](https://pubmed.ncbi.nlm.nih.gov/8343954). [S2CID](/source/S2CID_(identifier)) [10295196](https://api.semanticscholar.org/CorpusID:10295196).

- Roche PA, Teletski CL, Stang E, Bakke O, Long EO (September 1993). ["Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC47401). *Proceedings of the National Academy of Sciences of the United States of America*. **90** (18): 8581–8585. [Bibcode](/source/Bibcode_(identifier)):[1993PNAS...90.8581R](https://ui.adsabs.harvard.edu/abs/1993PNAS...90.8581R). [doi](/source/Doi_(identifier)):[10.1073/pnas.90.18.8581](https://doi.org/10.1073%2Fpnas.90.18.8581). [PMC](/source/PMC_(identifier)) [47401](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC47401). [PMID](/source/PMID_(identifier)) [8397411](https://pubmed.ncbi.nlm.nih.gov/8397411).

## External links

- [CD74+protein,+human](https://meshb.nlm.nih.gov/record/ui?name=CD74+protein%2C+human) at the U.S. National Library of Medicine [Medical Subject Headings](/source/Medical_Subject_Headings) (MeSH)

- [Overview](https://www.bio.davidson.edu/Courses/immunology/Students/spring2006/McCracken/HLA-DM.html) at [Davidson College](/source/Davidson_College) (student generated)

- [School of Crystallography](http://www.cryst.bbk.ac.uk/pps97/assignments/projects/coadwell/007.htm) [Archived](https://web.archive.org/web/20230601015056/https://www.cryst.bbk.ac.uk/pps97/assignments/projects/coadwell/007.htm) 2023-06-01 at the [Wayback Machine](/source/Wayback_Machine) The Invariant Chain

- Human [*CD74*](https://genome.ucsc.edu/cgi-bin/hgTracks?db=hg38&singleSearch=knownCanonical&position=CD74) genome location and [*CD74*](https://genome.ucsc.edu/cgi-bin/hgGene?db=hg38&hgg_type=knownGene&hgg_gene=CD74) gene details page in the [UCSC Genome Browser](/source/UCSC_Genome_Browser).

v t e PDB gallery 1icf: CRYSTAL STRUCTURE OF MHC CLASS II ASSOCIATED P41 II FRAGMENT IN COMPLEX WITH CATHEPSIN L 1iie: HLA-DR ANTIGENS ASSOCIATED INVARIANT CHAIN 1l3h: NMR structure of P41icf, a potent inhibitor of human cathepsin L

v t e Proteins: clusters of differentiation (see also list of human clusters of differentiation) 1–50 CD1 a-c 1A 1B 1D 1E CD2 CD3 γ δ ε CD4 CD5 CD6 CD7 CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33 CD34 CD35 CD36 CD37 CD38 CD39 CD40 CD41 CD42 a b c d CD43 CD44 CD45 CD46 CD47 CD48 CD49 a b c d e f CD50 51–100 CD51 CD52 CD53 CD54 CD55 CD56 CD57 CD58 CD59 CD61 CD62 E L P CD63 CD64 A B C CD66 a b c d e f CD68 CD69 CD70 CD71 CD72 CD73 CD74 CD78 CD79 a b CD80 CD81 CD82 CD83 CD84 CD85 a d e h j k CD86 CD87 CD88 CD89 CD90 CD91 CD92 CD93 CD94 CD95 CD96 CD97 CD98 CD99 CD100 101–150 CD101 CD102 CD103 CD104 CD105 CD106 CD107 a b CD108 CD109 CD110 CD111 CD112 CD113 CD114 CD115 CD116 CD117 CD118 CD119 CD120 a b CD121 a b CD122 CD123 CD124 CD125 CD126 CD127 CD129 CD130 CD131 CD132 CD133 CD134 CD135 CD136 CD137 CD138 CD140b CD141 CD142 CD143 CD144 CD146 CD147 CD148 CD150 151–200 CD151 CD152 CD153 CD154 CD155 CD156 a b c CD157 CD158 (a d e i k) CD159 a c CD160 CD161 CD162 CD163 CD164 CD166 CD167 a b CD168 CD169 CD170 CD171 CD172 a b g CD174 CD177 CD178 CD179 a b CD180 CD181 CD182 CD183 CD184 CD185 CD186 CD191 CD192 CD193 CD194 CD195 CD196 CD197 CDw198 CDw199 CD200 201–250 CD201 CD202b CD204 CD205 CD206 CD207 CD208 CD209 CDw210 a b CD212 CD213a 1 2 CD217 CD218 (a b) CD220 CD221 CD222 CD223 CD224 CD225 CD226 CD227 CD228 CD229 CD230 CD233 CD234 CD235 a b CD236 CD238 CD239 CD240CE CD240D CD241 CD243 CD244 CD246 CD247 CD248 CD249 251–300 CD252 CD253 CD254 CD256 CD257 CD258 CD261 CD262 CD263 CD264 CD265 CD266 CD267 CD268 CD269 CD271 CD272 CD273 CD274 CD275 CD276 CD278 CD279 CD280 CD281 CD282 CD283 CD284 CD286 CD288 CD289 CD290 CD292 CDw293 CD294 CD295 CD297 CD298 CD299 301–350 CD300A CD301 CD302 CD303 CD304 CD305 CD306 CD307 CD309 CD312 CD314 CD315 CD316 CD317 CD318 CD320 CD321 CD322 CD324 CD325 CD326 CD327 CD328 CD329 CD331 CD332 CD333 CD334 CD335 CD336 CD337 CD338 CD339 CD340 CD344 CD349 CD350 351–371 CD351 CD352 CD353 CD354 CD355 CD357 CD358 CD360 CD361 CD362 CD363 CD364 CD365 CD366 CD367 CD368 CD369 CD370 CD371 Category Commons

---
Adapted from the Wikipedia article [CD74](https://en.wikipedia.org/wiki/CD74) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/CD74?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.